Interested In Sinphar PharmaceuticalLtds Upcoming NT1.00 Dividend You Have Four Days Left - Simply Wall St
| 1734 Stock | TWD 31.45 0.05 0.16% |
Slightly above 61% of Sinphar Pharmaceutical's investor base is looking to short. The analysis of current outlook of investing in Sinphar Pharmaceutical Co suggests that many traders are alarmed regarding Sinphar Pharmaceutical's prospects. Sinphar Pharmaceutical's investing sentiment can be driven by a variety of factors including economic data, Sinphar Pharmaceutical's earnings reports, geopolitical events, and overall market trends.
Sinphar Pharmaceutical stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Sinphar daily returns and investor perception about the current price of Sinphar Pharmaceutical Co as well as its diversification or hedging effects on your existing portfolios.
Sinphar |
Interested In Sinphar PharmaceuticalLtds Upcoming NT1.00 Dividend You Have Four Days Left Simply Wall St
Read at news.google.com
 |
Sinphar Pharmaceutical Fundamental Analysis
We analyze Sinphar Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinphar Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinphar Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Sinphar Pharmaceutical is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Sinphar Pharmaceutical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sinphar Pharmaceutical stock to make a market-neutral strategy. Peer analysis of Sinphar Pharmaceutical could also be used in its relative valuation, which is a method of valuing Sinphar Pharmaceutical by comparing valuation metrics with similar companies.
Peers
Sinphar Pharmaceutical Related Equities
| 1711 | Everlight Chemical | 0.23 |
| ||
| 4133 | Abnova Taiwan | 0.33 |
| ||
| 4108 | Phytohealth Corp | 0.59 |
| ||
| 4106 | Wellell | 0.60 |
| ||
| 3705 | YungShin Global | 4.77 |
|
Additional Tools for Sinphar Stock Analysis
When running Sinphar Pharmaceutical's price analysis, check to measure Sinphar Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinphar Pharmaceutical is operating at the current time. Most of Sinphar Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sinphar Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinphar Pharmaceutical's price. Additionally, you may evaluate how the addition of Sinphar Pharmaceutical to your portfolios can decrease your overall portfolio volatility.